# US 2024/0197660 A1 · Compositions of micronized solabegron and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197660 A1
- Document ID: US20240197660A1
- Status: Published application
- Kind: A1
- Application number: 18/550,790
- Filed: 2022-03-31
- Published: 2024-06-20
- Earliest claimed: 2021-03-31
- Assignees: B3Ar Therapeutics, Inc.
- Applicants: B3Ar Therapeutics, Inc.
- Inventors: Raymond E. STEVENS, Jr.; Dale BENNYHOFF
- Web page: https://patentgrep.com/patent/US20240197660A1

## CPC

- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are compositions and methods for treating overactive bladder. In some embodiments, the composition comprises an effective amount of micronized solabegron or a pharmaceutically acceptable salt or a derivative thereof. In some embodiments the micronized solabegron particles have a particle size of about 0.1 micron to 30 microns. In some embodiments, the administration of the pharmaceutical composition is twice daily.

## Claims

### Claim 1

A pharmaceutical composition consisting of about 100 mg to about 125 mg of micronized solabegron or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein at least 90% of the micronized solabegron has a particle size of about 0.1 micron to 30 microns and wherein the pharmaceutical composition is an immediate release composition.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient is selected from the group consisting of a filler, a disintegrant, a binder, a wetting agent, a lubricant, and a glidant, or combinations thereof.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the excipient is selected from the group consisting of mannitol, poloxamer 188, methyl cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and polyvinyl alcohol, or combinations thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the excipient is selected from the group consisting of sucrose, wheat starch, microcrystalline cellulose, talc, lactose monohydrate, calcium carbonate, titanium dioxide, stearic acid, croscarmellose sodium, povidone, polyethylene glycol 8000, colloidal silicon dioxide, ferric oxide, carboxymethylcellulose sodium, white wax, magnesium stearate, and carnauba wax or combinations thereof.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the excipient is selected from the group consisting of colloidal anhydrous silica, calcium hydrogen phosphate dihydrate, cellulose microcrystalline, hypromellose, magnesium stearate, sodium starch glycolate (pH 3.0 to 5.0), stearic acid, and titanium dioxide or combinations thereof.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is a tablet, a capsule, a granule, or a powder.

### Claim 8

(canceled)

### Claim 9

A method of treating overactive bladder or one or more symptoms thereof, in a subject in need thereof, comprising orally administering to the subject a pharmaceutical composition consisting of a therapeutically effective amount of about 100 mg to about 125 mg of micronized solabegron or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein at least 90% of solabegron particles have a particle size of about 0.1 micron to 30 microns and wherein the pharmaceutical composition is an immediate release composition.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pharmaceutical composition is administered twice daily.

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The method of claim 9, wherein the one or more symptoms are selected from increased frequency of urinary urgency, nocturia, increase in urinary micturition frequency, and urinary incontinence, and combination thereof.

### Claim 13 (depends on 9)

The method of claim 9, further comprising administering to the subject one or more additional therapeutic agents selected from the group consisting of alpha adrenoceptor blockers, botulinum toxin, purinergics, cannabinoids, transient receptor potential (TRP) protein inhibitors, prostaglandins, percutaneous tibial nerve stimulators, sacral nerve stimulators, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, beta-3 adrenoreceptor agonists, and combination thereof.

### Claim at position 14

-17. (canceled)

### Claim 18 (depends on 9)

The method of claim 9, wherein the pharmaceutical composition achieves a target AUC48 of about 17,000 ng·hr/mL to about 23,000 ng·hr/mL.

### Claim 19 (depends on 18)

The method of claim 18, wherein the therapeutically effective amount of micronized solabegron is about 100 mg.

### Claim 20 (depends on 19)

The method of claim 19, wherein the pharmaceutical composition is administered twice a day.

### Claim at position 18

-23. (canceled)

### Claim 24 (depends on 1)

The pharmaceutical composition of claim 1, wherein the micronized solabegron has a particle size of about 0.1 micron to 10 microns.

### Claim 25 (depends on 18)

The method of claim 18, wherein the therapeutically effective amount of micronized solabegron is about 125 mg.

### Claim 26 (depends on 25)

The method of claim 25, wherein the pharmaceutical composition is administered twice a day.
